Fate Therapeutics, Inc. (FATE) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:FATEFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
(1.9)
Fate Therapeutics, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Revenue GrowthFATE has had growing revenue for the last 5 years |
|
Price to Book (PBV) RatioOvervalued price-to-book. FATE stock price is overvalued by more than 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)FATE equity is higher than it's debt. |
|
RevenueFATE has positive revenue for last 5 years |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Net Income GrowthFATE has never had growing net income. |
|
Net IncomeFATE never has positive net income for 2 years. |
|
Dividend YieldFATE has low dividend yield (0%). |
|
Return of AssetsFATE has low return of asset (-39.23%). |
|
Return of EquityFATE has low return of equity (-48.78%). |
|
Return of Invested CapitalFATE has low ROIC. |
Competitors
Fate Therapeutics, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 55,846,000 USD
- Cost
- 272,840,000 USD
- Net Income
- -212,151,000 USD
- Profit Margin
- -379.89%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -213,574,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 495.83% |
Long Term Liabilities
| Liquidity/Current Ratio | 515.05% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -4x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 515.05% |
| Cash Ratio | 78.98% |
| Debt Ratio | 30.87% |
| Debt-Equity Ratio (DER) | 44.66% |
| Net Profit Margin (NPM) | -425.98% |
| Return of Assets (ROA) | -39.23% |
| Return of Equity (ROE) | -48.78% |
| Return on Capital Employed (ROCE) | -48.55% |
| Days of Sales Outstanding (DSO) | 54.07 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
Fate Therapeutics, Inc. Executives
CEO
- CEO Name
- Mr. John Wolchko
Management
Fate Therapeutics, Inc. Profile
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Additional Information
- Company name
- Fate Therapeutics, Inc.
- Symbol
- NASDAQ:FATE
- Exchange
- NASDAQ Global Market
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
3535 General Atomics Ct Ste 200
San Diego
CALIFORNIA
US
92131 - Website
- https://www.fatetherapeutics.com